Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation

Abstract Treatment‐free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation in patients with deep molecular response (DMR) is a paramount goal in the current chronic myeloid leukemia (CML) therapeutic strategy. The best DMR level by real‐time quantitative PCR (RT‐qPCR) for TKI discon...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Simona Bernardi, Michele Malagola, Camilla Zanaglio, Nicola Polverelli, Elif Dereli Eke, Mariella D’Adda, Mirko Farina, Cristina Bucelli, Luigi Scaffidi, Eleonora Toffoletti, Clara Deambrogi, Fabio Stagno, Micaela Bergamaschi, Luca Franceschini, Elisabetta Abruzzese, Maria Domenica Divona, Marco Gobbi, Francesco Di Raimondo, Gianluca Gaidano, Mario Tiribelli, Massimiliano Bonifacio, Chiara Cattaneo, Alessandra Iurlo, Domenico Russo
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Wiley 2019-05-01
Cyfres:	Cancer Medicine
Pynciau:	chronic myeloid leukemia digital PCR (dPCR) minimal residual disease (MRD) monitoring treatment‐free remission (TFR) tyrosine kinase inhibitors (TKI) discontinuation
Mynediad Ar-lein:	https://doi.org/10.1002/cam4.2087
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!